<p>海吉亚医疗控股（港交所代码：6078）在股东批准回购最多 10% 已发行股本的授权后，启动了一项大规模的股票回购，表明其对股东回报的更明确承诺。</p>
<p>查看我们对海吉亚医疗控股的最新分析。</p>
<p>此次回购是在市场疲软的背景下进行的，过去三年总股东回报率大幅下滑。然而，最近 7 天股价回报率为 9.64%，这表明投资者在重新评估其增长和风险特征时，情绪可能正在转变。</p>
<p>如果这次回购让你重新考虑医疗行业的机会，现在可能是探索其他基本面稳健且有潜在重新评级的医疗股票的好时机。</p>
<p>随着利润仍在增长，股价远低于分析师目标，管理层现在开始回购股票，海吉亚是否被低估，还是投资者已经考虑了其所有未来增长？</p>
<h2>15.3 倍的市盈率，这合理吗？</h2>
<p>在盈利方面，海吉亚的市盈率为 15.3 倍，相较于其同行和更广泛的香港医疗行业显得昂贵。</p>
<p>市盈率将当前股价与每股收益进行比较。这是一个简单的衡量标准，显示投资者为每单位利润支付的金额，而该业务的收入相对稳定，主要来自肿瘤医院。</p>
<p>与香港医疗行业平均市盈率 12 倍以及其直接同行组的更低 7.8 倍相比，海吉亚的定价显得相对昂贵。然而，相较于估计的合理市盈率 18 倍，如果盈利增长如预期实现，市场有空间将该股票重新评级至更高的基准。</p>
<p>探索海吉亚医疗控股的 SWS 合理比率</p>
<p><strong>结果：市盈率 15.3 倍（被高估）</strong></p>
<p>然而，持续的股价疲软以及任何盈利增长或肿瘤需求的放缓可能迅速削弱重新评级的理由。</p>
<p>了解海吉亚医疗控股叙述中的关键风险。</p>
<h2>价值的另一种视角</h2>
<p>我们的 DCF 模型描绘了一个截然不同的图景，表明海吉亚的交易价格约低于估计的合理价值 61%，大约为 32 港元。这意味着市场可能在严重低估其长期现金生成能力。这种谨慎是否合理，还是一个显而易见的机会？</p>
<p>了解 SWS DCF 模型如何得出其合理价值。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f28e4047-c264-44be-b2c8-24139d6d0e1f/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f28e4047-c264-44be-b2c8-24139d6d0e1f/chart/dcf"/></p>
<p>6078 截至 2025 年 12 月的折现现金流</p>
<p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看海吉亚医疗控股）。我们展示了完整的计算过程。您可以在您的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 917 只基于现金流的被低估股票。如果您保存筛选器，我们甚至会在新公司匹配时提醒您——这样您就不会错过潜在机会。</p>
<h2>构建您自己的海吉亚医疗控股叙述</h2>
<p>如果您对这个故事有不同的看法或想自己深入研究数字，您可以在几分钟内构建一个量身定制的视图，按照您的方式进行。</p>
<p>一个好的起点是我们的分析，强调投资者对海吉亚医疗控股的两个关键回报的乐观预期。</p>
<h2>准备好更多高信念的想法吗？</h2>
<p>在市场不再等您之前，通过扫描 Simply Wall Street 上的其他机会，将海吉亚置于背景中，在那里新鲜的想法与清晰的数据支持分析相结合。</p>
<ul>
<li>通过浏览这些 917 只基于现金流的被低估股票，寻找潜在的错误定价，这些股票可能提供比您关注的通常大型股更强的上行空间。</li>
<li>通过筛选这 24 只处于软件、自动化和长期结构性增长交汇点的 AI 小盘股，抓住突破性创新的机会。</li>
<li>通过关注这 13 只收益率超过 3% 的股息股票，增强您的收入流，这些股票结合了可靠的派息和能够承受更艰难条件的资产负债表。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>移动基础设施用于国防和灾难</p>
<p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内提供 5G、ISR 和雷达的全自动塔，适用于任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

海吉亚医疗

<p>海吉亚医疗控股（SEHK:6078）已启动了一项重大股票回购计划，回购其已发行股本的最多 10%。此举是在市场表现疲软的背景下进行的，最近股价上涨了 9.64%，显示出投资者情绪有所改善。尽管市盈率高达 15.3 倍，但根据折现现金流模型，该股票可能被低估，估计其交易价格低于公允价值的 61%。投资者被鼓励探索其他基本面强劲的医疗股票</p>

<p>Hygeia Healthcare Holdings (SEHK:6078) has kicked off a sizeable share buyback after shareholders approved a mandate to repurchase up to 10% of its issued share capital, signaling a clearer commitment to shareholder returns.</p>
<div class="lb-trans"><p>海吉亚医疗控股（港交所代码：6078）在股东批准回购最多 10% 已发行股本的授权后，启动了一项大规模的股票回购，表明其对股东回报的更明确承诺。</p>
</div><p>See our latest analysis for Hygeia Healthcare Holdings.</p>
<div class="lb-trans"><p>查看我们对海吉亚医疗控股的最新分析。</p>
</div><p>The buyback comes after a weak stretch in the market, with the share price down sharply on a 3 year total shareholder return basis. However, the recent 7 day share price return of 9.64% suggests sentiment may be turning as investors reassess its growth and risk profile.</p>
<div class="lb-trans"><p>此次回购是在市场疲软的背景下进行的，过去三年总股东回报率大幅下滑。然而，最近 7 天股价回报率为 9.64%，这表明投资者在重新评估其增长和风险特征时，情绪可能正在转变。</p>
</div><p>If this buyback has you rethinking opportunities in healthcare, it could be a good moment to explore other healthcare stocks with resilient fundamentals and potential for rerating.</p>
<div class="lb-trans"><p>如果这次回购让你重新考虑医疗行业的机会，现在可能是探索其他基本面稳健且有潜在重新评级的医疗股票的好时机。</p>
</div><p>With profits still growing, the share price far below analyst targets and management now buying back stock, is Hygeia quietly undervalued, or are investors already factoring in all of its future growth?</p>
<div class="lb-trans"><p>随着利润仍在增长，股价远低于分析师目标，管理层现在开始回购股票，海吉亚是否被低估，还是投资者已经考虑了其所有未来增长？</p>
</div><h2>Price to Earnings of 15.3x, Is it justified?</h2>
<div class="lb-trans"><h2>15.3 倍的市盈率，这合理吗？</h2>
</div><p>On earnings, Hygeia trades at a 15.3x price to earnings multiple, which screens as expensive relative to both its peers and the wider Hong Kong healthcare sector.</p>
<div class="lb-trans"><p>在盈利方面，海吉亚的市盈率为 15.3 倍，相较于其同行和更广泛的香港医疗行业显得昂贵。</p>
</div><p>The price to earnings ratio compares the current share price with per share earnings. It is a simple gauge of how much investors pay for each unit of profit in a business built on relatively steady oncology hospital revenues.</p>
<div class="lb-trans"><p>市盈率将当前股价与每股收益进行比较。这是一个简单的衡量标准，显示投资者为每单位利润支付的金额，而该业务的收入相对稳定，主要来自肿瘤医院。</p>
</div><p>Hygeia looks richly priced when stacked against the Hong Kong healthcare industry average multiple of 12x and an even lower 7.8x for its direct peer group. However, versus an estimated fair price to earnings of 18x, there is room for the market to re rate the stock closer to that higher benchmark if earnings growth delivers as forecast.</p>
<div class="lb-trans"><p>与香港医疗行业平均市盈率 12 倍以及其直接同行组的更低 7.8 倍相比，海吉亚的定价显得相对昂贵。然而，相较于估计的合理市盈率 18 倍，如果盈利增长如预期实现，市场有空间将该股票重新评级至更高的基准。</p>
</div><p>Explore the SWS fair ratio for Hygeia Healthcare Holdings</p>
<div class="lb-trans"><p>探索海吉亚医疗控股的 SWS 合理比率</p>
</div><p><strong>Result: Price to Earnings of 15.3x (OVERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：市盈率 15.3 倍（被高估）</strong></p>
</div><p>However, sustained share price weakness and any slowdown in earnings growth or oncology demand could quickly undermine the case for a valuation re-rating.</p>
<div class="lb-trans"><p>然而，持续的股价疲软以及任何盈利增长或肿瘤需求的放缓可能迅速削弱重新评级的理由。</p>
</div><p>Find out about the key risks to this Hygeia Healthcare Holdings narrative.</p>
<div class="lb-trans"><p>了解海吉亚医疗控股叙述中的关键风险。</p>
</div><h2>Another View on Value</h2>
<div class="lb-trans"><h2>价值的另一种视角</h2>
</div><p>Our DCF model paints a very different picture, suggesting Hygeia is trading about 61% below an estimated fair value of roughly HK$32. That implies the market may be heavily discounting its long term cash generation. Is this caution justified, or is it an opportunity hiding in plain sight?</p>
<div class="lb-trans"><p>我们的 DCF 模型描绘了一个截然不同的图景，表明海吉亚的交易价格约低于估计的合理价值 61%，大约为 32 港元。这意味着市场可能在严重低估其长期现金生成能力。这种谨慎是否合理，还是一个显而易见的机会？</p>
</div><p>Look into how the SWS DCF model arrives at its fair value.</p>
<div class="lb-trans"><p>了解 SWS DCF 模型如何得出其合理价值。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f28e4047-c264-44be-b2c8-24139d6d0e1f/chart/dcf" alt="" original-src="https://images.simplywall.st/company/f28e4047-c264-44be-b2c8-24139d6d0e1f/chart/dcf"/></p>
<p>6078 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>6078 截至 2025 年 12 月的折现现金流</p>
</div><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hygeia Healthcare Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 917 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p>
<div class="lb-trans"><p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看海吉亚医疗控股）。我们展示了完整的计算过程。您可以在您的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 917 只基于现金流的被低估股票。如果您保存筛选器，我们甚至会在新公司匹配时提醒您——这样您就不会错过潜在机会。</p>
</div><h2>Build Your Own Hygeia Healthcare Holdings Narrative</h2>
<div class="lb-trans"><h2>构建您自己的海吉亚医疗控股叙述</h2>
</div><p>If you see the story differently or want to dig into the numbers yourself, you can build a tailored view in just minutes, Do it your way.</p>
<div class="lb-trans"><p>如果您对这个故事有不同的看法或想自己深入研究数字，您可以在几分钟内构建一个量身定制的视图，按照您的方式进行。</p>
</div><p>A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Hygeia Healthcare Holdings.</p>
<div class="lb-trans"><p>一个好的起点是我们的分析，强调投资者对海吉亚医疗控股的两个关键回报的乐观预期。</p>
</div><h2>Ready for more high conviction ideas?</h2>
<div class="lb-trans"><h2>准备好更多高信念的想法吗？</h2>
</div><p>Before markets move on without you, put Hygeia in context by scanning other opportunities on Simply Wall Street, where fresh ideas meet clear, data backed analysis.</p>
<div class="lb-trans"><p>在市场不再等您之前，通过扫描 Simply Wall Street 上的其他机会，将海吉亚置于背景中，在那里新鲜的想法与清晰的数据支持分析相结合。</p>
</div><ul>
<li>Target potential mispricings by running through these 917 undervalued stocks based on cash flows that may offer stronger upside than the usual large cap names on your radar.</li>
<li>Capitalize on breakthrough innovation by filtering for these 24 AI penny stocks positioned at the intersection of software, automation and long term structural growth.</li>
<li>Strengthen your income stream by focusing on these 13 dividend stocks with yields &gt; 3% that combine reliable payouts with balance sheets built to withstand tougher conditions.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过浏览这些 917 只基于现金流的被低估股票，寻找潜在的错误定价，这些股票可能提供比您关注的通常大型股更强的上行空间。</li>
<li>通过筛选这 24 只处于软件、自动化和长期结构性增长交汇点的 AI 小盘股，抓住突破性创新的机会。</li>
<li>通过关注这 13 只收益率超过 3% 的股息股票，增强您的收入流，这些股票结合了可靠的派息和能够承受更艰难条件的资产负债表。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内提供 5G、ISR 和雷达的全自动塔，适用于任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

海吉亚医疗控股（SEHK:6078）：在启动大规模股票回购后重新评估其估值